---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-24-000004"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:14:06.552421+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Akebia discloses preliminary unaudited Auryxia net product revenue for FY2023 in JPM conference presentation

## Summary
- Presentation at 42nd Annual J.P. Morgan Healthcare Conference on Jan 11, 2024 includes preliminary Auryxia revenue.
- Preliminary unaudited net product revenue for Auryxia for fiscal year ended Dec 31, 2023; exact figures not in filing text.
- Investor and analyst meetings coincide with the J.P. Morgan Healthcare Conference starting Jan 8, 2024.

## SEC filing metadata
- accession: 0001517022-24-000004
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000004/0001517022-24-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000004/akba-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-24-000004
- JSON: https://secwatch.observer/filing/0001517022-24-000004.json
- Plain text: https://secwatch.observer/filing/0001517022-24-000004.txt

## Key facts
- Earnings Releases
  Akebia Therapeutics, Inc. reported preliminary financial results for the fiscal year ended December 31, 2023.
  - Period: the fiscal year ended December 31, 2023
  - Result: preliminary results
  source text: John P. Butler, President and Chief Executive Officer of Akebia Therapeutics, Inc. (the “Company”), plans to present the information in the presentation attached hereto as Exhibit 99.1 (the “Presentation”) at the 42 nd Annual J.P. Morgan Healthcare Conference on January 11, 2024 at 11:15 a.m. PST, which includes preliminary unaudited net product revenue for Auryxia® cumulative and for the fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000004/0001517022-24-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.